Pfizer Still Has A Hangover After COVID

Written by

rummu

in

For most of the last decade, Pfizer was a slow-growing pharmaceutical giant. Revenue hovered around $50-55 billion annually, margins were healthy, and investors largely viewed the company as a dependable dividend payer rather than a growth story. Then COVID happened. Pfizer became one of the biggest winners of the pandemic, with Comirnaty and Paxlovid generating […]

You are unauthorized to view this page.

  • Rummu provides data, analysis, and tools for research purposes only. The information presented does not constitute financial advice, a recommendation, or an offer to buy or sell any securities. It does not take into account individual objectives, financial situations, or needs. You are solely responsible for your own investment decisions.

More posts